Bionxt Solutions
  • About Us
    • About Us
    • Our Team
  • Our Products
    • Point-of-Care Diagnostics
    • Drug Delivery
    • Psychedelics
  • News
  • Investors
    • Investor Information
    • Shareholder Documents
  • Contact
XPhyto Lab Worker with protective eyewear
  • Home
  • News

Category: Drug Delivery

View all Posts

Show All Press Releases Diagnostics Psychedelics Drug Delivery

Drug Delivery, Press Releases

XPhyto reports excellent Rotigotine in-vitro/ex-vivo results for Parkinson’s disease treatment

Oct 18, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Drug Delivery, Press Releases

XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study

Oct 11, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Drug Delivery, Press Releases

XPhyto adds pharmaceutical manufacturing expert Dr. Florian A. Sahr to its European team

Jun 8, 2022

Vancouver, Canada, and Uttenweiler, Germany (June 8, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Drug Delivery, Press Releases

XPhyto reports product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease

May 9, 2022

Vancouver, Canada, and Uttenweiler, Germany (May 9, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Drug Delivery, Press Releases

XPhyto reports market and product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease

Apr 4, 2022

Vancouver, Canada, and Uttenweiler, Germany (April 4, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Drug Delivery, Press Releases

XPhyto Epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips

Dec 15, 2021

Vancouver, Canada, and Uttenweiler, Germany (December 15, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Drug Delivery, Press Releases

XPhyto Reports Development Update for its Drug Delivery Business

Oct 12, 2021

Rotigotine transdermal skin patch optimization and pivotal study planning underwayRotigotine patch manufacturing, sales and marketing in preparationCannabinoid oral dissolvable film (ODF) programs advanced, CBD ODF...

Continue Reading

Drug Delivery, Press Releases

XPhyto Provides Update on Drug Formulation and Development Business

May 13, 2021

Rotigotine transdermal human pilot study successfully completed; program advancing to pivotal studyLand purchased for construction of commercial drug manufacturing facility in Germany Vancouver, Canada, and...

Continue Reading

Drug Delivery, Press Releases

XPhyto Announces Drug Formulation Strategy And 2021 Milestones

Jan 28, 2021

Construction of commercial drug manufacturing facility in GermanyFour clinical studies in neurological indications in 2021Development of oral biosensor and contract development & manufacturingPsychedelic transdermal and...

Continue Reading

Drug Delivery, Press Releases

Update On Contract Drug Delivery Programs

Oct 19, 2020

Vancouver, Canada (October 19, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next-generation bioscience company, is pleased to...

Continue Reading

Drug Delivery, Press Releases

Update On Oral Thin Film Drug Delivery Programs

Sep 22, 2020

Vancouver, Canada (September 22, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next-generation bioscience company, is pleased to...

Continue Reading

Drug Delivery, Press Releases

Parkinsons Transdermal Patch

XPhyto Provides Update On Parkinsons’ Transdermal Patch

Aug 25, 2020

Vancouver, Canada (August 25, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next generation bioscience company, is pleased...

Continue Reading
Page 1 of 212
Scientist looking in magnifying glass XPhyto

Be in the know. Get our press releases and latest news first.

Hear about our latest research, products, exclusive partnerships & more.

Unsubscribe anytime. View our Privacy Policy for additional information.

  • About Bionxt
  • Our Team
  • Our Products
  • Careers
  • Investor Information
  • Company/Investor Presentation
  • Press Releases
  • Request Info
  • Legal Information
  • Cautionary Note
  • Privacy Policy
  • Contact
Xphyto test tubes in laboratory footer
Copyright © 2023 Bionxt Solutions
This website uses cookies and third party services. By clicking “Accept”, you consent to the use of all cookies
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT